Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

NCT02785939 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT02785939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02785939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2/3
Overall status
Completed
Start date
September 30, 2014
Completion date
June 30, 2019
Enrollment
53 (actual)
Sites
1,065

Conditions

As the registry lists them; a condition with its own page is linked.

ccnd1 gene amplification, ccnd2 gene amplification, ccnd3 gene amplification, cdk4 gene amplification, recurrent squamous cell lung carcinoma, stage iv squamous cell lung carcinoma ajcc v7